Video

A reduction in the costly dialysis-like treatment of lipoprotein apheresis looks possible for FH patients following results from a study with the PCSK9 inhibitor alirocumab. Professor Patrick M Moriarty (University of Kansas Medical Center, USA) discusses the implications.

New advances in hypertension, including a breakthrough for the treatment of resistant hypertension is discussed by Dr Terry McCormack, while Professor Barbara Casadei discusses the different presentation and co-morbidities of cardiovascular disease in women.

An update of new treatments for heart failure is given by Dr Afzal Sohaib talking to Dr Jubin Joseph. Take home messages for general practitioners in the fields of heart failure and anticoagulation are given by Dr Yassir Javaid.

The latest news from lipid-lowering studies with monoclonal antibodies – the PCSK9 inhibitors – is discussed by Dr Peter Lansberg. An update on new devices including a leadless pacemaker and a bioresabsorbable scaffold is reported by Drs Afzal Sohaib and Jubin Joseph, who also talk about advances in the treatment of acute myocardial infarction.

Our latest podcasts are intended to provide an overview of familial hypercholesterolaemia (FH), while reviewing current best treatments as well as some novel options for the future.

Three experts give their personal highlights of the 2015 European Atherosclerosis Society Congress in our podcast.

• Professor Naveed Sattar discusses lifestyle and risk (00:10)
• Professor Børge Nordestgaard discusses the clinical importance of lipoprotein (a) (05:37)
• Professor Derick Raal discusses the launch of the Familial Hypercholesterolaemia Studies Collaboration (10:27)